Home  |  About JAPTR |  Editorial board  |  Search |  Ahead of print  |  Current issue  |  Archives |  Submit article  |  Instructions  |  Subscribe  |  Advertise  |  Contacts  |Login 
Users Online: 357   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
     

 Table of Contents  
EDITORIAL
Year : 2014  |  Volume : 5  |  Issue : 4  |  Page : 151  

Recent advances in ocular drug delivery system


Editor, Journal of Advanced Pharmaceutical Technology and Research (JAPTR), Editor-in-Chief, SPER Times Secretary, Society of Pharmaceutical Education and Research, 22-C, Jawahar Colony, Gwalior - 474 001, M.P., India

Date of Web Publication15-Oct-2014

Correspondence Address:
Upendra Nagaich
Editor, Journal of Advanced Pharmaceutical Technology and Research (JAPTR), Editor-in-Chief, SPER Times Secretary, Society of Pharmaceutical Education and Research, 22-C, Jawahar Colony, Gwalior - 474 001, M.P.
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2231-4040.143022

Rights and Permissions

How to cite this article:
Nagaich U. Recent advances in ocular drug delivery system. J Adv Pharm Technol Res 2014;5:151

How to cite this URL:
Nagaich U. Recent advances in ocular drug delivery system. J Adv Pharm Technol Res [serial online] 2014 [cited 2019 Jul 19];5:151. Available from: http://www.japtr.org/text.asp?2014/5/4/151/143022

Dear Friends,

Recent progressions have been made in pharmacological therapies to treat ocular disorders such as glaucoma, conjunctivitis, diabetic macular edema and retinal vascular occlusions to improve the diagnosis for these disorders. Due to these advances, there is a great deal of interest in minimally invasive delivery methods, which has generated rapid developments in the field of ocular drug delivery. Conventional eye drops have been restricted to eye and therapeutic drug concentrations in target tissues are not maintained for a long time. So, a vital need emerges to fabricate ocular drug delivery systems that provide controlled-release for the treatment of chronic diseases, and also enhances patient's and doctor's convenience to reduce the dosing frequency and invasive treatment. Current developments include delivery to both anterior and posterior segments of the eye. Traditional ocular dosage forms have been overcame by advance drug delivery techniques to anterior segment like contact lens, cul-de-sac inserts, punctual plugs, subconjunctival/episcleral implants, while to posterior segment includes intravitreal implants like Durasert™ Technology System, Novadur™ Technology, I-vation™ TA, NT-501 and injectable particulate systems as IBI-20089, RETAAC, Cortiject® (NOVA63035, Novagali Pharma S.A.), Visudyne® have revolutionized the ocular delivery of drugs. Furthermore, physical devices like iontophoresis and micro-electromechanical intraocular drug delivery device are non-invasive techniques of ocular drug delivery, therefore, avoids the complications of a surgical implantation or frequent dosing of intravitreal injections. Iontophoresis involves delivery of drug by the application of weak direct current which takes the charged molecules across the sclera, into the vitreous and choroid. An opposite charge ground electrode is kept elsewhere on the body to complete the circuit. EyeGate Pharmaceuticals, Inc., (Waltham, MA, US) has sign up for a pivotal phase III study of EGP-437 for dry eye syndrome therapy. EGP-437 is a dexamethasone phosphate for delivery using the EyeGate II® Delivery System. Micro-electromechanical intraocular drug delivery device is a micro-electromechanical systems (MEMS) discovered for the therapy of chronic and refractory ocular diseases. Drug solution can be refilled in MEMS device, imparting a long-term drug therapy and avoid repeated surgical treatments. Replenish, Inc., (Pasadena, CA, US) set up to go into trials for Food and Drug Administration approval for a refillable and programmable pump which can be implanted in the eye to deliver drug for glaucoma. In addition, encapsulated cell technology has found its application directly to the posterior segment of the eye. It involves entrapment of immunologically isolated cells with hollow fibers or microcapsules. Certainly, further considerations should be made with the most efficacious combinations of optimal drugs, dose, route, and drug release pattern (sustained-release, pulsatile-release, or controlled-release responding to a trigger) according to the pathophysiology and progressive courses of the targeted disease.

 
  Authors Top


Dr. Upendra Nagaich



This article has been cited by
1 A review on recent advancements in ophthalmology devices: Currently in market and under clinical trials
Rajini Nagaraj,Divya Rani Bijukumar,Benjamin Mathew,Evan A. Scott,Mathew Thoppil Mathew
Journal of Drug Delivery Science and Technology. 2019;
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   Authors

 Article Access Statistics
    Viewed1717    
    Printed51    
    Emailed0    
    PDF Downloaded8033    
    Comments [Add]    
    Cited by others 1    

Recommend this journal